middle.news
Imugene and JW Therapeutics Unite to Target Solid Tumors with Novel ‘Mark and Kill’ Therapy
9:19am on Thursday 27th of November, 2025 AEDT
•
Biotechnology
Read Story
Imugene and JW Therapeutics Unite to Target Solid Tumors with Novel ‘Mark and Kill’ Therapy
9:19am on Thursday 27th of November, 2025 AEDT
Key Points
Strategic collaboration between Imugene and JW Therapeutics
Combination of onCARlytics (CF33-CD19) virus and Carteyva® CAR-T therapy
Preclinical studies followed by Phase 1 trial in China
First-in-class approach inducing CD19 expression on solid tumors
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE